



NDA 021880/S-018

SUPPLEMENT APPROVAL

Celgene Corporation
Attention: Marion Ceruzzi, Ph.D.
Director, Regulatory Affairs
86 Morris Avenue
Summit, New Jersey 07901

Dear Dr. Ceruzzi:

Please refer to your Supplemental New Drug Application (sNDA) dated February 6, 2009, received February 9, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for REVLIMID[®] (lenalidomide).

We acknowledge receipt of your amendments dated February 11, June 11, and December 11, 2009; April 9, and October 8, 2010.

The April 9, 2010, submission constituted a complete response to our December 11, 2009, action letter.

This "Prior Approval" supplemental new drug application provides for updated information to the package insert with efficacy and safety data from the final analyses from the following studies:

CC-5013-MM-009 "A Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Multiple Myeloma Patients (United States and Canada)"

and

CC-5013-MM-010 "A Multi-Center, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Multiple Myeloma Patients (European Union, Australia, and Israel)".

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert, text for the patient package insert) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications for this NDA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Amy Baird, Regulatory Project Manager, at (301) 796-4969.

Sincerely,

{See appended electronic signature page}

Ann T. Farrell, M.D.
Acting Director
Division of Hematology Products
Office of Oncology Drug Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANN T FARRELL
10/12/2010